A systematic review and meta-analysis presented at the 2026 American College of Cardiology Scientific Session evaluated whether tafamidis was associated with improved survival in patients aged 80 years and...
July 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
The FDA approval provides physicians with a once-daily oral PCSK9 inhibitor option to reduce LDL-C in adults with high cholesterol, including those with heterozygous familial hypercholesterolemia.
The FDA approval provides physicians with a once-daily oral PCSK9 inhibitor option to reduce LDL-C in adults with high cholesterol, including those with heterozygous familial hypercholesterolemia.
A new ACC/AHA clinical practice guideline on managing adults with congenital heart disease updates its 2018 recommendations by integrating evidence from 2017 to 2024 and emphasizing specialized...
A phase 2 clinical trial found that ataciguat, a soluble guanylate cyclase activator, may slow aortic valve calcification and help preserve cardiac function in patients with moderate calcific aortic valve...
The FDA is seeking a cap on nicotine levels in cigarettes and certain tobacco products at minimally or nonaddictive levels. This initiative, if finalized, would be what the FDA calls a “significant step”...
